Chugai Pharmaceutical Co., Ltd. (CHGCY)

Market Cap	83.67B -11.7%
Revenue (ttm)	8.12B +5.7%
Net Income	2.84B +10.3%
EPS	1.73 +10.2%
Shares Out	n/a
PE Ratio	29.42
Forward PE	n/a
Dividend	66.94 (266.59%)
Ex-Dividend Date	Jun 29, 2026

Volume	17,271
Average Volume	328,152
Open	25.39
Previous Close	24.74
Day's Range	25.27 - 25.56
52-Week Range	19.50 - 34.84
Beta	0.56
RSI	47.63
Earnings Date	Apr 24, 2026

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 5,104
• Stock Exchange: OTCMKTS
• Ticker Symbol: CHGCY

Financial Performance

In 2025, Chugai Pharmaceutical's revenue was 1.26 trillion, an increase of 7.46% compared to the previous year's 1.17 trillion. Earnings were 434.01 billion, an increase of 12.06%.

Financial numbers in JPY